OOIR: Observatory of International Research

Papers

(The H4-Index of British Journal of Cancer is 54. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Advancing radiomics from contrast-enhanced mammography in breast cancer	219
The EXO1/Polη/Polι axis as a promising target for miR-3163-mediated attenuation of cancer stem-like cells in non-small cell lung carcinoma	169
Clinicopathological and molecular characteristics of RSPO fusion-positive colorectal cancer	151
Hepatitis B virus X protein promotes MAN1B1 expression by enhancing stability of GRP78 via TRIM25 to facilitate hepatocarcinogenesis	142
Years of life lost due to cancer in the United Kingdom from 1988 to 2017	142
Proactive breast cancer risk assessment in primary care: a review based on the principles of screening	140
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study)	133
Correction: YY1 targets tubulin polymerisation-promoting protein to inhibit migration, invasion and angiogenesis in pancreatic cancer via p38/MAPK and PI3K/AKT pathways	129
Correction: Wnt/ERK/CDK4/6 activation in the partial EMT state coordinates mammary cancer stemness with self-renewal and inhibition of differentiation	128
Breast cancer risk prediction with a modified BOADICEA model in Danish women	119
Extranodal extension in lung adenocarcinoma: pathological insights and its implication as a histological marker of clinical aggressiveness	116
Capecitabine combined with immunotherapy as maintenance therapy improves survival in recurrent/metastatic nasopharyngeal carcinoma: a retrospective cohort study	111
Correction to: Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells	109
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer	106
Investigation of the gut microbiome, bile acid composition and host immunoinflammatory response in a model of azoxymethane-induced colon cancer at discrete timepoints	101
Neoplasm risk in individuals with neurofibromatosis 1 – a Danish nationwide cohort study with long-term follow-up	101
Extruded small extracellular vesicles: splinters of circulating tumour cells may promote cancer metastasis?	98
Diagnostic accuracy of combinatorial mRNA biomarkers for non-invasive detection and therapy monitoring of oral and oropharyngeal SCC	93
Assessments of social vulnerability on laryngeal cancer treatment & prognosis in the US	91
Fibroblast activation protein-targeted near-infrared photoimmunotherapy depletes immunosuppressive cancer-associated fibroblasts and remodels local tumor immunity	90
Integrated genomic and transcriptomic analysis reveals the activation of PI3K signaling pathway in HPV-independent cervical cancers	90
DRP1 inhibition-mediated mitochondrial elongation abolishes cancer stemness, enhances glutaminolysis, and drives ferroptosis in oral squamous cell carcinoma	88
Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial	84
A very-hot food and beverage thermal exposure index and esophageal cancer risk in Malawi and Tanzania: findings from the ESCCAPE case–control studies	83
Normal weight obesity, circulating biomarkers and risk of breast cancer: a prospective cohort study and meta-analysis	83

Hit it hard: qualitative patient perspectives on the optimisation of immune checkpoint inhibition	83
Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer	82
Navigating therapeutic strategies: HPV classification in head and neck cancer	81
Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)	81
Advances in cancer immunotherapy: adoptive cell therapy and immune cell engagers in solid tumours	79
Comprehensive assessment of actionable genomic alterations in primary colorectal carcinoma using targeted next-generation sequencing	77
Identifying health conditions associated with an increased risk of pancreatic ductal adenocarcinoma at medium term in nationwide electronic health records of primary care physicians	77
Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value	74
Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate	74
The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer	73
Genomic ALK alterations in primary and relapsed neuroblastoma	72
Metabolic adaptations in prostate cancer	70
Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer	69
Targeting mitochondrial oxidative phosphorylation: lessons, advantages, and opportunities	69
Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analy	68
Metastasis-associated fibroblasts in peritoneal surface malignancies	67
Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer	67
Surveillance after childhood cancer: are survivors with an increased risk for cardiomyopathy regularly followed-up?	67
Genetic landscape of stage II melanoma identifies CBL as a new driver gene and prognostic biomarker	65
Abemaciclib plus fulvestrant in treating hormone-receptor positive, HER2-negative advanced breast cancer—comparing real-world outcomes in England to the MONARCH-2 trial	64
Oxaliplatin induces pyroptosis in hepatoma cells and enhances antitumor immunity against hepatocellular carcinoma	61
Somatic hits in mismatch repair genes in colorectal cancer among non-seminoma testicular cancer survivors	61
Prognostic relevance of the neurological symptom burden in brain metastases from breast cancer	60
DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors	59
Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification	58
A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer	58
Deep learning analysis of histopathological images predicts immunotherapy prognosis and reveals tumour microenvironment features in non-small cell lung cancer	58
Evidence into practice: a national cohort study of NICE-recommended oncological drug therapy utilisation among women diagnosed with invasive breast cancer in England	55
Serum 25-hydroxyvitamin D concentrations and colorectal cancer incidence in adults with type 2 diabetes	55
Long-term trends in incidence, characteristics and prognosis of screen-detected and interval cancers in women participating in the Dutch breast cancer screening programme	54